Receive our newsletter – data, insights and analysis delivered to you
  1. News
  2. Company News
August 16, 2018updated 06 Dec 2021 9:27am

Novocure and US Oncology Research partner for PANOVA-3 trial

Novocure has partnered with US Oncology Research to conduct the PANOVA-3 trial, a Phase lll study evaluating the efficacy of Tumor Treating Fields in combination with nab-paclitaxel and gemcitabine for the treatment of patients with unresectable locally advanced pancreatic cancer.

Novocure has partnered with US Oncology Research to conduct the PANOVA-3 trial, a Phase lll study evaluating the efficacy of Tumor Treating Fields in combination with nab-paclitaxel and gemcitabine for the treatment of patients with unresectable locally advanced pancreatic cancer.

As part of the collaboration, US Oncology Research, which is supported by The US Oncology Network, will open ten clinical trial sites to enrol patients for the PANOVA-3 trial.

Novocure chief science officer and Research and Development head Dr Eilon Kirson said: “Our strategic collaboration with US Oncology Research is an important milestone as we aim to bring better treatment options to patients with pancreatic cancer.

“We believe this relationship will accelerate enrolment of patients in our PANOVA-3 trial.”

A total of 556 patients with unresectable locally advanced pancreatic cancer are expected to be enrolled in the pivotal, randomised, and open-label PANOVA-3 trial.

“We believe this relationship will accelerate enrolment of patients in our PANOVA-3 trial.”

The trial will include patients who have an Eastern Cooperative Oncology Group (ECOG) score of 0-2 and no prior progression or treatment.

Content from our partners
The importance of reference products in biosimilar trials, and how to source them
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success

Patients in the experimental arm of the trial will use a Tumor Treating Fields delivery system tuned to 150kHz for a minimum of 18 hours a day until the disease progresses.

The trial’s primary trial endpoint is overall survival, while its secondary endpoints comprise progression-free survival, local progression-free survival, objective response rate, one-year survival rate, quality of life, pain-free survival, resectability rate and toxicity.

PANOVA-3 trial principal investigator Daniel Von Hoff said: “Pancreatic cancer is one of the most aggressive forms of cancer and was the third leading cause of cancer death in the US last year.

“I believe Tumor Treating Fields has the potential to improve survival in this disease.”

Tumor Treating Fields is a cancer therapy that is designed to use electric fields tuned to specific frequencies to interrupt cell division, thereby inhibiting tumour growth and causing affected cancer cells to die.

Related Companies

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU